GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (LTS:0OB3) » Definitions » Price-to-Owner-Earnings

Valneva SE (LTS:0OB3) Price-to-Owner-Earnings : (As of Jun. 06, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Valneva SE Price-to-Owner-Earnings?

As of today (2024-06-06), Valneva SE's share price is €3.854. Valneva SE does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Valneva SE's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Valneva SE was 1529.41. The lowest was 2.56. And the median was 30.65.


LTS:0OB3's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.81
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-06), Valneva SE's share price is €3.854. Valneva SE's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.19. Therefore, Valneva SE's PE Ratio for today is At Loss.

As of today (2024-06-06), Valneva SE's share price is €3.854. Valneva SE's EPS without NRI for the trailing twelve months (TTM) ended in was €-0.82. Therefore, Valneva SE's PE Ratio without NRI for today is At Loss.

During the past 13 years, Valneva SE's highest PE Ratio without NRI was 322.00. The lowest was 0.00. And the median was 56.00.


Valneva SE Price-to-Owner-Earnings Historical Data

The historical data trend for Valneva SE's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE Price-to-Owner-Earnings Chart

Valneva SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 110.29 - - -

Valneva SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Valneva SE's Price-to-Owner-Earnings

For the Biotechnology subindustry, Valneva SE's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Valneva SE's Price-to-Owner-Earnings falls into.



Valneva SE Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Valneva SE's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.854/-1.40
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valneva SE  (LTS:0OB3) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Valneva SE Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Valneva SE's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Valneva SE (LTS:0OB3) Business Description

Address
6 Rue Alain Bombard, Saint-Herblain, FRA, 44800
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, & third-party products; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The majority is from the Commercialized vaccines segment & geographically from the United States.

Valneva SE (LTS:0OB3) Headlines

No Headlines